Aspire-Lakewood Holdings is developing a patent-pending delivery technology

that can be applied to many active pharmaceutical ingredients (APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements.

  • Drug delivery technology for rapid sublingual absorption and entry into the bloodstream
  • Enhance the pharmacokinetic performance of APIs, supplements and nutraceuticals into the bloodstream to increase bioavailability, improve speed of onset and reduce side effects
  • Multiple ℞ applications in heart attack/stroke, anxiety, antiplatelet, nausea, and others
  • Omnibus patent and four provisional patents filed for approved therapeutics in large addressable markets
  • Lead Rx Product Candidate: Sublingual High Dose Aspirin followed by Alprazolam (Generic Xanax®)
  • Lead Consumer Product: BUZZ BOMB™ Caffeine
  • Focused on commercialization through partnerships, licensing and internal development